Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Johnson and Johnson
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: May 27, 2022

MINOCIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Minocin patents expire, and what generic alternatives are available?

Minocin is a drug marketed by Bausch, Triax Pharms, Lederle, and Rempex. and is included in five NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in twenty-two countries.

The generic ingredient in MINOCIN is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Paragraph IV (Patent) Challenges for MINOCIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MINOCIN Injection minocycline hydrochloride 100 mg/vial 050444 1 2020-10-16

US Patents and Regulatory Information for MINOCIN

MINOCIN is protected by two US patents.

Patents protecting MINOCIN

Tetracycline compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS

Tetracycline compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch MINOCIN minocycline hydrochloride CAPSULE;ORAL 050649-001 May 31, 1990 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rempex MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Triax Pharms MINOCIN minocycline hydrochloride CAPSULE;ORAL 050315-002 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rempex MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MINOCIN

See the table below for patents covering MINOCIN around the world.

Country Patent Number Title Estimated Expiration
Japan 2013529201 See Plans and Pricing
Portugal 2568987 See Plans and Pricing
Japan 2016145253 テトラサイクリン組成物 (TETRACYCLINE COMPOSITIONS) See Plans and Pricing
Mexico 347919 COMPOSICIONES DE TETRACICLINA. (TETRACYCLINE COMPOSITIONS.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Harvard Business School
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.